50BA Stock Overview
A clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bicycle Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.55 |
| 52 Week High | US$26.00 |
| 52 Week Low | US$5.45 |
| Beta | 1.6 |
| 1 Month Change | 26.89% |
| 3 Month Change | -38.11% |
| 1 Year Change | -62.62% |
| 3 Year Change | -77.26% |
| 5 Year Change | n/a |
| Change since IPO | -67.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| 50BA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 9.4% | 1.1% | 3.4% |
| 1Y | -62.6% | -14.9% | 15.0% |
Return vs Industry: 50BA underperformed the German Biotechs industry which returned -14.9% over the past year.
Return vs Market: 50BA underperformed the German Market which returned 15% over the past year.
Price Volatility
| 50BA volatility | |
|---|---|
| 50BA Average Weekly Movement | 12.7% |
| Biotechs Industry Average Movement | 6.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 50BA's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 50BA's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 305 | Kevin Lee | www.bicycletherapeutics.com |
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company’s products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical.
Bicycle Therapeutics plc Fundamentals Summary
| 50BA fundamental statistics | |
|---|---|
| Market cap | €551.17m |
| Earnings (TTM) | -€178.65m |
| Revenue (TTM) | €22.61m |
19.9x
P/S Ratio-2.5x
P/E RatioIs 50BA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 50BA income statement (TTM) | |
|---|---|
| Revenue | US$25.72m |
| Cost of Revenue | US$172.97m |
| Gross Profit | -US$147.24m |
| Other Expenses | US$55.98m |
| Earnings | -US$203.22m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.94 |
| Gross Margin | -572.44% |
| Net Profit Margin | -790.07% |
| Debt/Equity Ratio | 0% |
How did 50BA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/06 03:06 |
| End of Day Share Price | 2025/05/06 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bicycle Therapeutics plc is covered by 20 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| Kalpit Patel | B. Riley Securities, Inc. |
| Arlinda Lee | Canaccord Genuity |